SEC Form 4 FOF	RM 4	UNITED) STATES S	ECURITIES	SAND E	XCHANG	SE CO	OMMIS	SION					
				Washingt	on, D.C. 2054			OMB APPROVAL						
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).			Filed pursuar	t to Section 16(a) c tion 30(h) of the Inv	of the Securitie	_	Es Es	OMB Number: 323 Estimated average burden hours per response:						
1. Name and Address of Reporting Person [*] McBarron Paul				er Name and Ticke <u>acel Pharmac</u>			(Chec	5. Relationship of Reporting Person(s) to Iss (Check all applicable) X Director 10% Ow						
(Last) (First) (Middle) C/O CYCLACEL PHARMACEUTICALS, INC.,				e of Earliest Transac /2023	ction (Month/[Day/Year)	X	X Officer (give title Other (specify below) below) See Remarks						
200 CONNELL DRIVE, SUITE 1500				nendment, Date of	Original Filed	(Month/Day/Y	6. Indi Line) X	,						
(Street) BERKELEY HEIGHTS NJ 07922								Form filed by More than One Reporting Person						
(City)	(State)	(Zip)		Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.										
		Table I - Nor	n-Derivative S	ecurities Acq	uired, Disp	oosed of, o	or Ben	eficially	Owned					
Date			2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Disposed Of 5)	Acquirec (D) (Instr	i (A) or : 3, 4 and	5. Amount of Securities Beneficially Owned Followin	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Ownership			
					Code V	Amount	(A) or	Brico	Reported Transaction(s)		(Instr. 4)			

1. Name and Address of Reporting Person [*]					er Name and Ticke acel Pharmac		•			5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
McBarron P	<u>aui</u>		·				<u></u> ,	[- 1	X	Director	10% C	Owner			
(Last)	(First)	(Middle)		3. Date	of Earliest Transac	ction (M	onth/E	Day/Year)	X	Officer (give title below)	below	(specify)				
C/O CYCLAC	EL PHARMA	CEUTICALS, I	NC.,								See R	emarks				
200 CONNELL DRIVE, SUITE 1500					nendment, Date of	Original	Filed	(Month/Day/Y	6. Indiv Line)	6. Individual or Joint/Group Filing (Check Applicable Line)						
Street)										X	Form filed by One	e Reporting Pers	son			
BERKELEY HEIGHTS	BERKELEY NI 07922									Form filed by More than One Reporting Person						
				Rule 10b5-1(c) Transaction Indication												
(City)	(State)	(Zip)		Check this box to indicate that a transaction was m satisfy the affirmative defense conditions of Rule 10						to a contract, instruction or written plan that is intended to Instruction 10.						
		Table I - No	n-Derivat	ive S	ecurities Acqu	uired,	Disp	oosed of, o	or Ben	eficially	Owned					
I. Title of Security (Instr. 3) Date (Month/D				Execution Date,		3. Transaction Code (Instr. 8)		4. Securities Disposed Of 5)			5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership			
						Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)			
Common Stock ⁽¹⁾ 12/21/2						Р		1,886	A	\$3.315	33,378	D				

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

			(0.9.,	pulo,	ouno	, man	unt	o, optiono,			antico)				
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security		3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securitles Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Warrants (right to buy)	\$3.19	12/21/2023		Р		1,886		12/21/2023	12/21/2030	Common Stock	1,886	\$0 ⁽²⁾	1,886	D	

Explanation of Responses:

1. The Reporting Person purchased unregistered shares of the Issuer's common stock in a private placement, pursuant to a Securities Purchase Agreement between the Reporting Person and the Issuer.

2. Each share of common stock was purchased with an accompanying warrant at an aggregate purchase price of \$3.315 per share and accompanying warrant.

Remarks:

E. VP, Fin, CFO, COO and Secretary

/s/ Paul McBarron

** Signature of Reporting Person

12/26/2023 Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.